Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-03-06

FDA Approved: BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE — Original Application (Par Health USA, LLC)

View source ↗

Summary

FDA approved an original ANDA for a generic fixed-dose combination of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride (Par Health USA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride (Bismuth Subcitrate Potassium; Metronidazole; Tetracycline Hydrochloride)

Snippet

ORIG AP for BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE)